AaviGen
Tuesday, June 04, 2024
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 4
Founded in 2019, AaviGen GmbH is a pre-clinical stage biotechnology company specializing in the development of transformative gene therapy medicinal products (GTMPs) for genetic and acquired cardiovascular and cardiopulmonary diseases.
By leveraging a proprietary portfolio of genetically-engineered heart-specific Adeno-Associated Viruses (AAVs) to deliver therapeutic genes directly to the diseased heart cells via a single intravenous injection, AaviGen’s mission is to advance safe and effective precision GTMPs for heart-related ailments.
Integrating cutting-edge technologies with the interdisciplinary expertise of its founders – spanning clinical cardiology, virology and genetic vector engineering, GTMP development, health economics and regulatory affairs – AaviGen strives to address the unmet needs of millions of patients worldwide with its scalable vector platform and therapeutic pipeline, ultimately reshaping the clinical landscape of cardiovascular care.
Company Website:
https://aavigen.com
Lead Product in Development:
Heart-specific AAV-based GTMP against congestive heart failure improving cardiac contractile performance and energy metabolism and reversing arrhythmia propensity and maladaptive growth of the failing heart.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2-4
Company HQ City
Heidelberg
Company HQ State
Baden-Württemberg
Company HQ Country
Germany
CEO/Top Company Official
Prof. Dr. Patrick Most
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())